Aurinia Pharmaceuticals (AUPH) EBIT (2019 - 2026)

Aurinia Pharmaceuticals has reported EBIT for 8 years, with the latest figure at $41.4 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 89.6% year-over-year to $41.4 million; the trailing twelve-month figure through Mar 2026 stood at $124.5 million (up 309.33% YoY), and the FY2025 full-year result was $104.9 million, up 2338.4% from the prior year.
• EBIT for Q1 2026 stood at $41.4 million, up from $33.2 million in the prior quarter.
• The five-year high for EBIT was $41.4 million in Q1 2026, with the low at -$37.9 million in Q1 2022.
• Historically, EBIT has averaged -$3.6 million across 5 years, with a median of -$9.5 million in 2022.
• Annual changes were most pronounced in 2023 — EBIT slumped 71.21% — and 2025, when it surged 2091.55%.
• Aurinia Pharmaceuticals' EBIT stood at -$28.1 million in 2022, then fell by 5.6% to -$29.7 million in 2023, then surged by 94.38% to -$1.7 million in 2024, then surged by 2091.55% to $33.2 million in 2025, then grew by 24.62% to $41.4 million in 2026.
• The last three EBIT figures came in at $41.4 million (Q1 2026), $33.2 million (Q4 2025), and $29.7 million (Q3 2025), per Business Quant data.